EGFR and atrial fibrillation: Besides this on-target effect, ibrutinib deactivates several off-targets, e.g., EGFR, ErbB2, ITK, and TEC, which might contribute to the antitumor effect but, at the same time, result in adverse events, such as atrial fibrillation (AF) and bleeding [93,94].